|
| Clinical observation of modified Taohong Siwu Decoction for the treatment of isolated diastolic hypertension（qi stagnation and blood stasis type）in young and middle-aged people |
| Hits 53 Download times 8 Received:January 10, 2026 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2026.05.03 |
| Key Words
modified Taohong Siwu Decoction;young and middle-aged people;isolated diastolic hypertension;qi stagnation and blood stasis type |
| Author Name | Affiliation | E-mail | | JIA Xiaoxu | Department of Pharmacy, Ordos Traditional Chinese Medicine Hospital, Ordos 017010, China | | | LI Fangrui | Department of Traditional Chinese Medicine, China National Pharmaceutical Group Beifang Hospital, Baotou 014030, China | | | ZHANG Pengfei | Inner Mongolia Medical University, Hohhot 010110, China | | | GAO Simin | Inner Mongolia Medical University, Hohhot 010110, China | | | LIU Yuxin | Department of Rheumatology, Ordos Traditional Chinese Medicine Hospital, Ordos 017010, China | | | ZHENG Jiaquan | Department of Encephalopathy, Ordos Traditional Chinese Medicine Hospital, Ordos 017010, China | | | NIU Yaojie | Inner Mongolia Medical University, Hohhot 010110, China
Department of Rheumatology, Ordos Traditional Chinese Medicine Hospital, Ordos 017010, China | 1470371362@qq.com |
|
| Abstract
|
| [Objective] To observe the clinical efficacy of modified Taohong Siwu Decoction in treating isolated diastolic hypertension（qi stagnation and blood stasis type） in young and middle-aged people. [Methods] Young and middle-aged people with isolated diastolic hypertension of qi stagnation and blood stasis type who visited the outpatient and inpatient departments of Ordos Hospital of Traditional Chinese Medicine from September 2022 to November 2025 were selected. A randomized controlled method was used to randomly divided the enrolled patients into the control group，treatment group 1，and treatment group 2，with 37 cases in each group. The control group was treated with amlodipine besylate tablets，the treatment group 1 was treated with modified Taohong Siwu Decoction，and the treatment group 2 was treated with combined modified Taohong Siwu Decoction on the basis of the control group.The treatment period for three groups was 5 weeks. The blood pressure，heart rate，traditional Chinese medicine syndrome，lipid profile，and adverse reactions before and after treatment were evaluated and analyzed. [Results] After treatment，the systolic blood pressure（SBP），diastolic blood pressure（DBP），Chinese medicine syndrome score，and heart rate of the three groups of patients were significantly lower（P<0.05），and the treatment group 1 and treatment group 2 were significantly better than the control group in improving traditional Chinese medicine syndrome，efficacy rate of blood pressure reduction andreducing heart rates（P<0.05）. The treatment group 2 was significantly better than the control group in the markedefficacy rate of blood pressure reduction（P<0.05）. Treatment groups 1 and 2 significantly reduced total cholesterol（TC），triglycerides（TG），and low-density lipoprotein cholesterol（LDL-C，P<0.05），increased high-density lipoprotein cholesterol（HDL-C，P<0.05），and had significant differences compared with the control group in reducing TC，TG，LDL-C，and increasing HDL-C（P<0.05）.[Conclusion] The modified Taohong Siwu Decoction，when used alone or in combination with conventional Western medicine，demonstrates significant clinical efficacy in the treatment of middle-aged and young people with isolated diastolic hypertension of qi stagnation and blood stasis type. It can effectively lower patients’ blood pressure levels，improve their traditional Chinese medicine（TCM） syndromes and blood lipid profiles，and reduce their heart rates. Moreover，it outperforms conventional Western medicine treatment in terms of improving the efficacy on TCM syndromes，enhancing blood lipid profiles，and lowering heart rates. Additionally，this treatment regimen exhibits good clinical safety with no obvious adverse reactions observed，making it a viable option for clinical medication selection. |
|
|
|
|
|
|
|
